Borderline Resectable Classification Identifies Candidates for Conversion Therapy in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab.
Takeuchi Y, Sue M, Miyake N, Adachi T, Onishi H, Kawanaka M, Takaki A, Nouso K, Kariyama K, Nakamura S, Tanaka E, Tada T, Yasunaka T, Kuwaki K, Toshimori J, Iwado S, Moriya A, Hagihara H, Takabatake H, Sakata M, Otsuka M.
Takeuchi Y, et al.
Hepatol Res. 2026 Feb 9. doi: 10.1111/hepr.70138. Online ahead of print.
Hepatol Res. 2026.
PMID: 41661702